<DOC>
	<DOCNO>NCT00072475</DOCNO>
	<brief_summary>RATIONALE : Vatalanib may effective preventing development leukemia patient myelodysplastic syndrome . PURPOSE : This phase II trial study vatalanib see well work treat patient primary secondary myelodysplastic syndrome .</brief_summary>
	<brief_title>Vatalanib Treating Patients With Primary Secondary Myelodysplastic Syndromes</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response rate , term hematologic improvement complete partial remission , patient primary secondary ( therapy-related ) myelodysplastic syndrome treat vatalanib . - Determine time transformation acute myeloid leukemia ( least 20 % blast ) death patient treat drug . Secondary - Determine safety drug patient . - Determine duration response patient treated drug . - Determine cytogenetic response rate patient treat drug . - Determine overall progression-free survival patient treated drug . - Determine incidence infection require antibiotic hospitalization bleed require red blood cell transfusion patient treated drug . OUTLINE : This multicenter study . Patients stratified* accord risk group ( low grade [ refractory anemia without ringed sideroblast , refractory anemia excess blasts-1 , refractory cytopenia multilineage dysplasia without ringed sideroblast , myelodysplastic syndromes-unclassified , chronic myelomonocytic leukemia-1 ] v high grade [ refractory anemia excess blasts-2 chronic myelomonocytic leukemia-2 ] ) . NOTE : *Stratification accord risk ( low vs high ) occur 11/30/06 . Patients receive oral vatalanib daily day 1-28 . Courses repeat every 28 day absence disease progression unacceptable toxicity . Patients complete response ( CR ) receive 6 additional course documentation CR . Patients follow periodically 5 year study entry . PROJECTED ACCRUAL : Approximately 144 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Vatalanib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis primary secondary ( therapyrelated ) myelodysplastic syndromes* ( MDS ) , include follow cellular type : Refractory anemia ( RA ) ** RA excess blast ( RAEB ) 1 RA ring sideroblasts** Refractory cytopenia multilineage dysplasia Refractory cytopenia multilineage dysplasia ring sideroblasts* MDSunclassified** MDS associate isolated del ( 5q ) ** Chronic myelomonocytic leukemia ( CMML ) 1 NOTE : *Highrisk MDS ( i.e. , RAEB2 CMML2 ) close accrual 11/30/06 NOTE : **Accompanied least 1 follow laboratory value : hemoglobin le 10 g/dL , platelet count less 50,000/mm3 , absolute neutrophil count le 1,000/mm3 No prior leukemia ( i.e. , 20 % great blast ) No prior primary metastatic brain tumor carcinomatous meningitis PATIENT CHARACTERISTICS : Age 18 Performance status WHO 02 Life expectancy Not specify Hematopoietic See Disease Characteristics Hepatic Bilirubin great 1.5 time upper limit normal ( ULN ) AST great 2.5 time ULN APTT great 1.5 time ULN INR great 1.5 Renal Creatinine great 1.5 time ULN Urine protein negative urinalysis Protein 1+ dipstick allow provide total urine protein great 500 mg AND creatinine clearance least 50 mL/min 24hour urine collection Cardiovascular No significant cardiac vascular event within past 6 month , include follow : Acute myocardial infarction Unstable angina Uncontrolled hypertension Severe peripheral vascular disease ( e.g. , ischemic pain rest nonhealing ulcer wound ) New York Heart Association class IIIV congestive heart failure Cardiac arrhythmia Disseminated intravascular coagulation coagulopathies Deep vein arterial thrombosis No history congenital long QTc syndrome elongate QTc ( &gt; 450 msec male 470 female ) Pulmonary No pulmonary embolism within past 6 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective barrier contraception least 3 month study participation No need full anticoagulation within past 6 month No significant hemorrhage ( e.g. , visceral , gastrointestinal , genitourinary , gynecological ) require red blood cell transfusion within past month No known cerebral aneurysm , cerebrovascular malformation , CNS bleed No unhealed fracture , wound , ulcer PRIOR CONCURRENT THERAPY : Biologic therapy More 12 month since prior autologous stem cell allogeneic transplantation More 6 month since prior antiangiogenic agent More 1 month since prior interferon MDS More 1 month since prior hematopoietic growth factor MDS More 1 month since prior epoetin alfa ( EPO ) MDS More 1 month since prior thalidomide MDS More 1 month since prior immunotherapy MDS No concurrent prophylactic growth factor cytokine ( e.g. , filgrastim [ GCSF ] , sargramostim [ GMCSF ] , EPO EPOderivatives , interleukin11 ) Chemotherapy No prior lowdose antimetabolites MDS ( e.g. , hydroxyurea , azacitidine , lowdose cytarabine ) More 12 month since prior chemotherapy another disease* NOTE : *Not MDS leukemia Endocrine therapy More 1 month since prior corticosteroid MDS More 1 month since prior androgen MDS Radiotherapy More 12 month since prior radiotherapy another disease* NOTE : *Not MDS leukemia Surgery More 1 month since prior surgery , include needle biopsy visceral organ recover Bone marrow biopsy allow More 2 week since prior placement subcutaneous tunnel venous access device ( e.g. , PortaCath Hickman 's catheter ) adequately heal Other No prior cytotoxic therapy MDS More 1 month since prior administration follow medication MDS : Danazol Retinoids Amifostine Investigational agents No concurrent administration follow medication : Warfarin Heparin Derivatives heparin Other anticoagulant No concurrent grapefruit grapefruit juice</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>refractory cytopenia multilineage dysplasia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
</DOC>